Viewpoint Molecular Targeting
Viewpoint has developed a patented image-guided therapy for metastatic melanoma that is poised for Phase I clinical trials in humans.
Viewpoint develops injectable radiopharmaceuticals for diagnosis and therapy for cancer, with a focus on metastatic melanoma. Our products target cancer-cell specific properties, enabling a personalized-image-guided approach to optimizing treatments. Viewpoint has invented or licenses a portfolio of compounds at the preclinical and clinical stage of development, with its lead product poised to enter Phase I clinical imaging trials in humans.